Longitudinal Cohort Investigation of Mild Bilirubin-Related Biochemical Liver Changes Following SARS-CoV-2 Infection in a Specific Group of Wilson’s Disease Patients with Liver Cirrhosis - Scorecard - MDSpire
Advertisement
Longitudinal Cohort Investigation of Mild Bilirubin-Related Biochemical Liver Changes Following SARS-CoV-2 Infection in a Specific Group of Wilson’s Disease Patients with Liver Cirrhosis
Clinical Scorecard: Longitudinal Cohort Investigation of Mild Bilirubin-Related Biochemical Liver Changes Following SARS-CoV-2 Infection in a Specific Group of Wilson’s Disease Patients with Liver Cirrhosis
At a Glance
Category
Detail
Condition
Key Mechanisms
Impaired hepatic copper elimination leading to systemic copper accumulation and increased risk of severe COVID-19 outcomes, including potential long-term liver function impairment.
Target Population
Care Setting
Key Highlights
Patients with chronic liver disease, especially cirrhosis, are at higher risk for severe COVID-19 outcomes.
Elevated bilirubin and prolonged INR are predictors of poor outcomes in cirrhotic patients.
Wilson’s Disease patients may experience persistent health impairments post-COVID-19, including liver function issues.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Understanding the long-term effects of COVID-19 on liver function and copper metabolism is essential for managing this population, particularly in adjusting treatment plans.
Clinical Best Practices
Vaccination against COVID-19 is recommended for patients with chronic liver disease.
Prophylaxis for hepatitis B should be considered where appropriate.
Close monitoring of liver biochemistry, including specific tests like ALT, AST, and bilirubin levels, post-SARS-CoV-2 infection is recommended.
